The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
Open accessAbstract
This study evaluated azacitidine as treatment of minimal residual disease (MRD) determined by a sensitive donor chimerism analysis of CD34(+) blood cells to pre-empt relapse in patients with CD34(+) myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT). At a median of 169 days after HSCT, 20/59 prospectively screened patients experienced a decrease of CD34(+) donor chimerism to <80% and received four azacitidine cycles (75 mg/m(2)/day for 7 days) while in complete hematologic remission. A total of 16 patients (80%) responded with either increasing CD34(+) donor chimerism to ≥80% (n=10; 50%) or stabilization (n=6; 30%) in the absence of relapse. Stabilized patients and those with a later drop of CD34(+) donor chimerism to <80% after initial response were eligible for subsequent azacitidine cycles. A total of 11 patients (55%) received a median of 4 (range, 1-11) additional cycles. Eventually, hematologic relapse occurred in 13 patients (65%), but was delayed until a median of 231 days (range, 56-558) after initial decrease of CD34(+) donor chimerism to <80%. In conclusion, pre-emptive azacitidine treatment has an acceptable safety profile and can substantially prevent or delay hematologic relapse in patients with MDS or AML and MRD after allogeneic HSCT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663
The World Health Organization (WHO) classification of the myeloid neoplasms
Vardiman, J. W., Harris, N. L., & Brunning, R. D. (2002) · Blood · doi:10.1182/blood-2002-04-1199 · Cited by 2,197
Silverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., Stone, R. M., Nelson, D., Powell, B. L., DeCastro, C. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.117 · Cited by 1,825
Collins, R. H., Shpilberg, O., Drobyski, W. R., Porter, D. L., Giralt, S., Champlin, R., Goodman, S. A., Wolff, S. N., Hu, W., Verfaillie, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.433 · Cited by 1,237
Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8329 · Cited by 961
Schmid, C., Labopin, M., Nagler, A., Bornhäuser, M., Finke, J., Fassas, A., Volin, L., Gürman, G., Maertens, J., Bordigoni, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6053 · Cited by 516
Self-citationde Lima, M., Giralt, S., Thall, P. F., de Padua Silva, L., Jones, R. B., Komanduri, K., Braun, T. M., Nguyen, H. Q., Champlin, R., & Garcia‐Manero, G. (2010) · Cancer · doi:10.1002/cncr.25500 · Cited by 427
Graft-versus-leukemia reactions in allogeneic chimeras
Kolb, H.-J., Schmid, C., Barrett, A. J., & Schendel, D. J. (2004) · Blood · doi:10.1182/blood-2003-02-0342 · Cited by 397
Goodyear, O., Agathanggelou, A., Novitzky-Basso, I., Siddique, S., McSkeane, T., Ryan, G., Vyas, P., Cavenagh, J., Stankovic, T., Moss, P., et al. (2010) · Blood · doi:10.1182/blood-2009-11-249474 · Cited by 340
Choi, J., Ritchey, J., Prior, J. L., Holt, M., Shannon, W. D., Deych, E., Piwnica-Worms, D. R., & DiPersio, J. F. (2010) · Blood · doi:10.1182/blood-2009-12-257253 · Cited by 309
Thiede, C., Florek, M., Bornhäuser, M., Ritter, M., Mohr, B., Brendel, C., Ehninger, G., & Neubauer, A. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701779 · Cited by 257
Self-citationSilverman, L. R., Fenaux, P., Mufti, G. J., Santini, V., Hellström‐Lindberg, E., Gattermann, N., Sanz, G., List, A. F., Gore, S. D., & Seymour, J. F. (2011) · Cancer · doi:10.1002/cncr.25774 · Cited by 194
Bornhäuser, M., Oelschlaegel, U., Platzbecker, U., Bug, G., Lutterbeck, K., Kiehl, M. G., Schetelig, J., Kiani, A., Illmer, T., Schaich, M. A., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.007765 · Cited by 120
Self-citationMonitoring of minimal residual disease in acute myeloid leukemia
Kern, W., Haferlach, C., Haferlach, T., & Schnittger, S. (2007) · Cancer · doi:10.1002/cncr.23128 · Cited by 112
Relapse after Allogeneic Hematopoietic Cell Therapy
van den Brink, M. R. M., Porter, D. L., Giralt, S., Lu, S. X., Jenq, R. R., Hanash, A. M., & Bishop, M. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.10.023 · Cited by 97
Kröger, N. M., Bacher, U., Bader, P., Böttcher, S., Borowitz, M. J., Dreger, P., Khouri, I. F., Macapintac, H., Olavarría, E., Radich, J. P., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.06.008 · Cited by 86
Assessment of minimal residual disease in acute myeloid leukemia
Grimwade, D. J., Vyas, P., & Freeman, S. D. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833ed831 · Cited by 81
Towards individualized follow-up in adult acute myeloid leukemia in remission
Hokland, P., & Ommen, H. B. (2010) · Blood · doi:10.1182/blood-2010-09-303685 · Cited by 80
Surface marker abnormalities in myelodysplastic syndromes.
Elghetany, M. T. (1998) · PubMed · Cited by 72
Thiede, C., Bornhäuser, M., & Ehninger, G. (2004) · Acta Haematologica · doi:10.1159/000077555 · Cited by 69
Self-citationScott, B. L., & Deeg, H. J. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.051308.132852 · Cited by 57
Use of Epigenetic Modification to Induce FOXP3 Expression in Naïve T Cells
Moon, C., Kim, S. H., Park, K. S., Choi, B. K., Lee, H. S., Park, J. B., Choi, G. S., Kwan, J. H., Joh, J. W., & Kim, S. J. (2009) · Transplantation Proceedings · doi:10.1016/j.transproceed.2009.02.101 · Cited by 44
Minimal residual disease diagnostics in myeloid malignancies in the post transplant period
Bacher, U., Zander, A. R., Haferlach, T., Schnittger, S., Fehse, B., & Kröger, N. M. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.185 · Cited by 34
Cited by
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation
Toffalori, C., Zito, L., Gambacorta, V., Riba, M., Oliveira, G., Bucci, G., Barcella, M., Spinelli, O., Greco, R., Crucitti, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0400-z · Cited by 401
Adès, L., Itzykson, R., & Fenaux, P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61901-7 · Cited by 393
Short, N. J., Zhou, S., Fu, C., Berry, D. A., Walter, R. B., Freeman, S. D., Hourigan, C. S., Huang, X., Nogueras Gonzalez, G., Hwang, H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4600 · Cited by 390
de Witte, T., Bowen, D., Robin, M., Malcovati, L., Niederwieser, D., Yakoub-Agha, I., Mufti, G. J., Fenaux, P., Sanz, G., Martino, R., et al. (2017) · Blood · doi:10.1182/blood-2016-06-724500 · Cited by 379
Self-citationPlatzbecker, U., Middeke, J. M., Sockel, K., Herbst, R., Wolf, D., Baldus, C. D., Oelschlägel, U., Mütherig, A., Fransecky, L., Noppeney, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30580-1 · Cited by 345
Self-citation
Metadata
- Authors
- Platzbecker, U., Wermke, M., Radke, J., Oelschlaegel, U., Seltmann, F., Kiani, A., Klut, I.-M., Knoth, H., Röllig, C., Schetelig, J., Mohr, B., Graehlert, X., Ehninger, G., Bornhäuser, M., & Thiede, C.
- Venue
- Leukemia
- Published
- 2011-09-02
- Volume
- 26
- Issue
- 3
- Pages
- 381-389
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2021378114
- Cited by
- 389
- References
- 25
- FWCI
- 16.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.